5 Reasons to Stay Bullish Over the Near-TermPosted by Joe Fahmy
on April 12th, 2015
Share on StockTwits1) The NUMBER ONE criteria I use to evaluate the overall health of the market is the price action of leading stocks. Right now, I am finding many strong fundamental companies forming strong technical patterns. When I see this across many sectors, the market has […]
Some investors have been worried about a bubble in biotech stocks, and Wednesday’s sell off seemed to prove those fears.
Biotech stocks fell more than 3%, their biggest one-day drop this year.
But the industry is still one of the best-performing in the market: it’s up 35% over the past 12 months and 9.3% year-to-date, compared to year-to-date gains of 3% for […]
* * * *
4/11/2015 Investment House Report
* * * *MARKET ALERTS:Targets hit: None issuedBuy alerts: CLDX; FORMTrailing stops: None issuedStop alerts: None issuedThe market alert service is a premium level service where we issue intraday alerts relating to the general market conditions, when stocks hit action points (buy, stop, target, etc.), and when we see other information impacting the market […]
Link:
Message Board – Main Board
See which stocks are being affected by Social Media
[…]
Prom is a little while absent intended for Adriana Romano. Even so the 16-year-old witout a doubt appreciates anytime your lover moves into your Sayre Spot School gymnasium with Sayre, Pa., with May 20 of which not a soul more will likely be using the woman attire, some sort of strapless, bejeweled champagne-colored mermaid wedding gown that has a black […]
Biotech investors have been here before.
Stocks are lower on Wednesday and the high-flying biotech sector is leading the way down, with the iShares ETF that tracks the sector falling more than 3%.
And as the sector has weakened over the last several days, this sell off is starting to look at lot like the sell off we saw in the sector […]
Related MRKSunTrust’s Latest Comments On MerckMorgan Stanley’s Major Pharma Q1 PreviewMerck, NewLink Ebola Vaccine Enters Third Phase III Study – Analyst Blog(Zacks)Related Why Johnson & Johnson’s Strong Pharmaceutical Business Is A ConcernBenzinga’s Top UpgradesNew drug trial results positive(Investor’s Business Daily)In a report published Thursday, JMP Securities analysts expressed their views on Biotechnology stocks after the EASL abstracts were made available […]
Membership InformationDouglas Busch2015-02-19T16:15:12+00:00As many of you know, I’ve been extremely dedicated and passionate about ChartSmarter during the past three years. I am truly thankful to have added value to the portfolios of many traders and have taken pride in introducing new ideas to the conversation. As you can imagine, creating the game plan for each trading session has been a […]
Major updates in the biotech sector over the past four trading days were on the pipeline and regulatory front from companies like Alkermes (ALKS – Analyst Report) and Amgen (AMGN – Analyst Report) among others.Recap of the Week’s Most Important Stories1. Alkermes’ experimental schizophrenia treatment, ALKS 3831, fared well in a mid-stage study. Earlier this year, the company had said […]
Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces Reverse Stock Split and Nasdaq Listing SubmissionSAN DIEGO – April 8, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it will implement a 1-for-50 reverse split of its common stock. The implementation of the reverse stock […]
